MetaCap

Inhibrx Biosciences (INBX) vs Odyssey Therapeutics (ODTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Inhibrx Biosciences is the larger company by market cap ($1.02 billion vs $815.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

INBX-48.66%ODTX+3.29%
+81%+13%-55%
May 8, 20261 yearNov 20, 2026
INBX-48.66%ODTX+3.29%
+81%+13%-55%
May 4, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

INBX versus ODTX key metrics
MetricINBXODTX
Share price$68.97$16.96
Market cap$1.02B$815.23M
1-day change-7.21%-7.52%
YTD return-12.70%—
1-year return-17.82%—
EPS (TTM)$-9.06$-6.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.30M—
Revenue growth (YoY)+550.00%—
Net income (latest FY)$-140.06M—
Operating margin-10386.54%—
Net margin-10773.46%—
52-week high$155.29$29.05
52-week low$57.30$15.10
Distance from 52-week high-55.59%-41.62%
Analyst consensusnonestrong_buy
Avg. price target upside+286.65%+104.42%
Average volume305.96K329.31K
Shares outstanding14.77M48.07M
Employees109100
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Inhibrx Biosciences

INBX stock →

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

About Odyssey Therapeutics

ODTX stock →

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees

INBX vs ODTX FAQ

Which is bigger, Inhibrx Biosciences or Odyssey Therapeutics?

Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.02B compared with $815.23M for Odyssey Therapeutics (ODTX).

Are Inhibrx Biosciences and Odyssey Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons